Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Equity ETF median (66 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 23 Oct 2023 – 20 Aug 2026, limited by Mirae Asset Nifty 200 Alpha 30 ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Mirae Asset Nifty 200 Alpha 30 ETF | Nifty 500 |
|---|---|---|
| 23 Oct 2023 | ₹100.00 | ₹100.00 |
| 17 Jan 2024 | ₹126.62 | ₹115.39 |
| 12 Apr 2024 | ₹143.16 | ₹122.84 |
| 07 Jul 2024 | ₹171.07 | ₹136.11 |
| 01 Oct 2024 | ₹173.64 | ₹143.71 |
| 26 Dec 2024 | ₹158.75 | ₹132.81 |
| 22 Mar 2025 | ₹135.08 | ₹125.97 |
| 16 Jun 2025 | ₹150.91 | ₹136.75 |
| 10 Sep 2025 | ₹151.45 | ₹136.62 |
| 05 Dec 2025 | ₹153.92 | ₹141.13 |
| 01 Mar 2026 | ₹152.62 | ₹137.17 |
| 26 May 2026 | ₹157.20 | ₹135.58 |
| 20 Aug 2026 | ₹159.68 | ₹139.22 |
| Metric | Mirae Asset NAV ₹26.62 Very High risk ★★☆☆☆ 1Y | Category median Equity ETF · 66 funds |
|---|---|---|
| +5.19% | +3.95% | |
| — | +11.55% | |
| — | +10.41% | |
| — | +11.81% | |
| +18.02% | +8.19% | |
| +6.02% | — | |
| — | +13.71% | |
| — | +14.22% | |
| — | +12.98% | |
| Risk | ||
| 21.60% | 17.16% | |
| -0.06 | 0.22 | |
| -0.08 | 0.32 | |
| -30.00% | -20.98% | |
| Nifty 500 | — | |
| +3.84% | +0.65% | |
| 1.32 | 1.00 | |
| 139.5% | 101.0% | |
| 136.9% | 97.0% | |
| 0.77% | 0.37% | |
| ₹409.73Cr | ₹91.02Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| 23 Oct 2023 | — | |
| 30 | — | |
| 46.0% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.